Evidence map›Paper›PMID 20890948›Full record

ArticleHepatology (Baltimore, Md.)2010

E-cadherin antagonizes transforming growth factor β1 gene induction in hepatic stellate cells by inhibiting RhoA-dependent Smad3 phosphorylation.

Il Je Cho, Young Woo Kim, Chang Yeob Han, Eun Hyun Kim, Richard A Anderson, Young Sok Lee, Chang Ho Lee, Se Jin Hwang, Sang Geon Kim

Open access · greenAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Article
  15. Article
  16. Article
  17. Article
  18. 20Journal of ginseng research · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Il Je ChoInnovative Drug Research Center for Metabolic and Inflammatory Disease, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Young Woo Kim
Chang Yeob Han
Eun Hyun Kim
Richard A Anderson
Young Sok Lee
Chang Ho Lee
Se Jin Hwang
Sang Geon Kim
Hanyang University · KRSeoul National University · KRCatholic University of Korea · KRDaegu Haany University · KRUniversity of Wisconsin–Madison · US

Funding

Targeting of Phosphoinositide Signaling in Migration, Invasion and MetastasisR01GM057549 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI ANDERSON, RICHARD A. · 1998 to 2019
$5.7M
PI Signaling Role in Epithelial/Mesenchymal TransitionR01CA104708 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ANDERSON, RICHARD A. · 2004 to 2014
$2.9M
NCI NIH HHS R01 CA104708NIGMS NIH HHS R01 GM057549
6 · The paper itself

Abstract

unlabelledCadherins mediate cell-cell adhesion and catenin (ctn)-related signaling pathways. Liver fibrosis is accompanied by the loss of E-cadherin (ECAD), which promotes the process of epithelial-mesenchymal transition. Currently, no information is available about the inhibitory role of ECAD in hepatic stellate cell activation. Because of ECAD's potential for inhibiting the induction of transforming growth factor β1 (TGFβ1), we investigated whether ECAD overexpression prevents TGFβ1 gene induction; we also examined what the molecular basis could be. Forced expression of ECAD decreased α-smooth muscle actin and vimentin levels and caused decreases in the constitutive and inducible expression of the TGFβ1 gene and its downstream genes. ECAD overexpression decreased Smad3 phosphorylation, weakly decreased Smad2 phosphorylation, and thus inhibited Smad reporter activity induced by either treatment with TGFβ1 or Smad3 overexpression. Overexpression of a dominant negative mutant of ras homolog gene family A (RhoA) diminished the ability of TGFβ1 to elicit its own gene induction. Consistently, transfection with a constitutively active mutant of RhoA reversed the inhibition of TGFβ1-inducible or Smad3-inducible reporter activity by ECAD. Studies using the mutant constructs of ECAD revealed that the p120-ctn binding domain of ECAD was responsible for TGFβ1 repression. Consistently, ECAD was capable of binding p120-ctn, which recruited RhoA; this prevented TGFβ1 from increasing RhoA-mediated Smad3 phosphorylation. In the liver samples of patients with mild or severe fibrosis, ECAD expression reciprocally correlated with the severity of fibrosis.

conclusionOur results demonstrate that ECAD inhibits Smad3/2 phosphorylation by recruiting RhoA to p120-ctn at the p120-ctn binding domain, whereas the loss of ECAD due to cadherin switching promotes the up-regulation of TGFβ1 and its target genes, and facilitates liver fibrosis.

Indexed as

ActinsAnimalsCadherinsDimethylnitrosamineEpithelial-Mesenchymal TransitionFemaleHepatic Stellate CellsHumansLiver CirrhosisMaleMicePhosphorylationRatsrhoA GTP-Binding ProteinSmad2 ProteinSmad3 ProteinActinsCadherinsDimethylnitrosaminerhoA GTP-Binding ProteinSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor beta1

Identifiers

PMID20890948
PMCPMC3086490
OpenAlexW1983072760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.